keyword
MENU ▼
Read by QxMD icon Read
search

tocilizumab

keyword
https://www.readbyqxmd.com/read/28432157/effect-of-interleukin-6-inhibition-on-coronary-microvascular-and-endothelial-function-in-myocardial-infarction
#1
Espen Holte, Ola Kleveland, Thor Ueland, Gabor Kunszt, Marte Bratlie, Kaspar Broch, Annika E Michelsen, Bjørn Bendz, Brage H Amundsen, Svend Aakhus, Jan Kristian Damås, Lars Gullestad, Pål Aukrust, Rune Wiseth
OBJECTIVE: Interleukin-6 (IL-6) is a driver of inflammation and associated endothelial cell activation in acute coronary syndromes. We evaluated the effect of the IL-6 receptor antagonist tocilizumab on coronary microvascular function and endothelial dysfunction measured by coronary flow reserve (CFR) and markers of endothelial cell activation in patients with non-ST-elevation myocardial infarction (NSTEMI). METHODS: This substudy was part of a two-centre, double-blind, randomised, placebo-controlled trial evaluating the effect of a single dose of tocilizumab in NSTEMI...
April 21, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28431111/correction-of-abnormal-b-cell-subset-distribution-by-interleukin-6-receptor-blockade-in-polymyalgia-rheumatica
#2
Guillermo Carvajal Alegria, Valérie Devauchelle-Pensec, Yves Renaudineau, Alain Saraux, Jacques-Olivier Pers, Divi Cornec
Objectives.: The aim was to study lymphocyte subsets and circulating cytokines at diagnosis of PMR and after tocilizumab monotherapy. Methods.: Eighteen untreated patients with PMR were included in a prospective study and received 3-monthly tocilizumab infusions without glucocorticoids. Lymphocyte subset distribution was assessed by flow cytometry and serum cytokines were assayed by a 34-cytokine array and ELISA, at baseline and during follow-up. Baseline data were also compared with age- and sex-matched controls...
April 20, 2017: Rheumatology
https://www.readbyqxmd.com/read/28418334/juvenile-idiopathic-arthritis
#3
Kenan Barut, Amra Adrovic, Sezgin Şahin, Özgür Kasapçopur
Juvenile idiopathic arthritis is the most common chronic rheumatic disease of unknown aetiology in childhood and predominantly presents with peripheral arthritis. The disease is divided into several subgroups, according to demographic characteristics, clinical features, treatment modalities and disease prognosis. Systemic juvenile idiopathic arthritis, which is one of the most frequent disease subtypes, is characterized by recurrent fever and rash. Oligoarticular juvenile idiopathic arthritis, common among young female patients, is usually accompanied by anti-nuclear antibodie positivity and anterior uveitis...
April 5, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28413099/second-line-biologic-therapy-optimization-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis
#4
REVIEW
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Maurizio Benucci, Francesca Li Gobbi, Serena Guiducci, Rosario Foti, Marta Mosca, Delia Goletti
OBJECTIVE: The Italian board for the TAilored BIOlogic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA). METHODS: Systematic review of the literature to identify English-language articles on efficacy of second-line biologic choice in RA, PsA, and ankylosing spondylitis (AS). Data were extracted from available randomized, controlled trials, national biologic registries, national healthcare databases, post-marketing surveys, and open-label observational studies...
March 22, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28412711/biologic-disease-modifying-antirheumatic-drug-bdmard-induced-neutropenia-a-registry-from-a-retrospective-cohort-of-patients-with-rheumatic-diseases-treated-with-3-classes-of-intravenous-bdmard
#5
Francisco Espinoza, Pierre Le Blay, Bernard Combe
OBJECTIVE: To examine the rate, risks factors, and consequences of neutropenia induced by intravenous (IV) biologic disease-modifying antirheumatic drugs (bDMARD). METHODS: We conducted a retrospective cohort study in 499 patients with rheumatic diseases treated by IV abatacept (ABA), infliximab (IFX), or tocilizumab (TCZ). RESULTS: Rheumatoid arthritis (RA) was the most frequent diagnosis (72%). Fifty-two patients (10.4%) experienced at least 1 episode of neutropenia...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28406764/the-efficacy-of-tocilizumab-for-the-treatment-of-chinese-takayasu-s-arteritis
#6
Jiaxin Zhou, Zhe Chen, Jing Li, Yunjiao Yang, Jiuliang Zhao, Hu Chen, Min Liu, Fei Sun, Mengtao Li, Xinping Tian, Xiaofeng Zeng
OBJECTIVES: The aim of this study was to evaluate the efficacy and safety of tocilizumab (TCZ) in Chinese Takayasu's arteritis (TA) patients. METHODS: This was a single centre prospective study. Sixteen consecutive TA patients were included. Patients were treated with tocilizumab infusions with a dosage of 8mg/kg. Serum inflammation markers, including erythrocyte sedimentation rate (ESR) and hypersensitivity C reactive protein (hsCRP), were recorded at baseline and before each TCZ infusion...
April 10, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28401573/is-tocilizumab-a-potential-therapeutic-option-for-refractory-unicentric-castleman-disease
#7
Muhammad Bilal Abid, Rachel Peck, Muhammad Abbas Abid, Wesam Al-Sakkaf, Yuening Zhang, Giles S Dunnill, Konrad Staines, Iara-Maria Sequeiros, Lisa Lowry
Castleman disease is a rare lymphoproliferative disorder with 2 distinctly defined clinical forms. While multicentric Castleman disease (UCD) poses a potential therapeutic challenge, unicentric variant has historically been considered curable with surgical resection. Hence, little is known to guide management of patients with UCD, refractory to surgical resection and combination chemotherapy. We present a case of a patient, negative for HIV and HHV-8, who had an unsuccessful surgical intervention and no response to radiotherapy and chemotherapy...
April 11, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28396064/-erysipelas-without-fever-or-biologic-inflammation-during-tocilizumab-therapy
#8
M Yéléhé-Okouma, J Henry, N Petitpain, J-L Schmutz, P Gillet
BACKGROUND: Tocilizumab (TCZ) is a monoclonal antibody that inhibits the interleukin 6 (IL-6) signalling pathway. This treatment is extremely effective in rheumatoid arthritis (RA), which may well be accompanied by serious infections presenting misleading clinical pictures. Herein we report a case of a typical bacterial dermo-hypodermitis in a female patient treated with TCZ. PATIENTS AND METHODS: An 80-year-old woman treated with methotrexate (MTX) and TCZ for RA presented dermo-hypodermitis on her left leg 8 days after receiving her 13th infusion of TCZ...
April 7, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28393636/tocilizumab-postpones-the-start-of-hemodialysis-compared-to-conventional-oral-treatment-in-amyloid-a-amyloidosis-patients-with-advanced-renal-insufficiency-by-suppressing-serum-saa-levels
#9
Hiroshi Uda, Osamu Saiki
No abstract text is available yet for this article.
April 10, 2017: Amyloid: the International Journal of Experimental and Clinical Investigation
https://www.readbyqxmd.com/read/28389552/tocilizumab-combination-therapy-or-monotherapy-or-methotrexate-monotherapy-in-methotrexate-naive-patients-with-early-rheumatoid-arthritis-2-year-clinical-and-radiographic-results-from-the-randomised-placebo-controlled-function-trial
#10
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco
OBJECTIVE: Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104. METHODS: Methotrexate (MTX)-naive patients with early progressive RA were randomly assigned to double-blind 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo or placebo+MTX for 104 weeks. Patients not receiving 8 mg/kg TCZ and not achieving Disease Activity Score-28 joints (DAS28-erythrocyte sedimentation rate (ESR)) ≤3...
April 7, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28376912/head-to-head-comparison-of-aggressive-conventional-therapy-and-three-biological-treatments-and-comparison-of-two-de-escalation-strategies-in-patients-who-respond-to-treatment-study-protocol-for-a-multicenter-randomized-open-label-blinded-assessor-phase-4-study
#11
Daniel Glinatsi, Marte S Heiberg, Anna Rudin, Dan Nordström, Espen A Haavardsholm, Bjorn Gudbjornsson, Mikkel Østergaard, Till Uhlig, Gerdur Grondal, Kim Hørslev-Petersen, Ronald van Vollenhoven, Merete L Hetland
BACKGROUND: New targeted therapies and improved treatment strategies have dramatically improved the outcomes of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can induce stable remission or a low-active disease state that can be maintained with conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two de-escalation strategies in patients who respond to first-line therapy...
April 4, 2017: Trials
https://www.readbyqxmd.com/read/28374627/sirukumab-a-promising-therapy-for-rheumatoid-arthritis
#12
Eleftherios Pelechas, Paraskevi V Voulgari, Alexandros A Drosos
Rheumatoid arthritis (RA) is an autoimmune disease, which has a negative impact on the ability to perform activities daily. Interleukin-6 (IL-6) wields pleiotropic biological effects that are crucially implicated in the activation of acute inflammatory response. Sirukumab is a monoclonal antibody with high affinity for IL-6. Areas covered: In this review, the authors examine sirukumab as a novel agent and its potential use in the treatment of RA focusing on the available data. Data from Phase I to Phase III indicate that sirukumab is generally safe and well tolerated by the patients with decreased inflammatory response...
April 4, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28371836/differential-effects-of-biological-dmards-on-peripheral-immune-cell-phenotypes-in-patients-with-rheumatoid-arthritis
#13
Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Yusuke Miyazaki, Naoki Yunoue, Shigeru Iwata, Ippei Miyagawa, Shintaro Hirata, Kazuhisa Nakano, Kazuyoshi Saito, Yoshiya Tanaka
Objective.: The aim of this study was to assess the therapeutic effects of biological DMARDs (bDMARDs) on the diversity of immune cell phenotypes in peripheral blood of patients with RA. Methods.: Peripheral immune cell phenotypes were determined in 108 RA patients who were non-responsive to conventional DMARDs and 33 healthy control subjects by eight-colour flow cytometry. We also examined the correlation between the phenotypes and clinical findings and assessed the effects of 24-week treatment with bDMARDs...
March 27, 2017: Rheumatology
https://www.readbyqxmd.com/read/28371574/tofacitinib-suppresses-disease-activity-and-febrile-attacks-in-a-patient-with-coexisting-rheumatoid-arthritis-and-familial-mediterranean-fever
#14
Kevser Gök, Gizem Cengiz, Kemal Erol, Salih Ozgocmen
Familial Mediterranean fever (FMF) is the most common hereditary auto-inflammatory (periodic fever) syndrome, and usually successfully treated with colchicine. However, nearly 5-10% of FMF cases are resistant or intolerant to colchicine and treatment options are highly restricted in these cases. Biologics including anakinra, canakinumab, rilonacept, etanercept, infliximab, interferon-alpha, and tocilizumab are shown to have efficacy to control FMF attacks. Tofacitinib, a Janus kinase (JAK) inhibitor, is an orally administered non-biologic disease modifying anti-rheumatic drug for the treatment of rheumatoid arthritis (RA)...
January 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28361123/tocilizumab-anti-il-6r-suppressed-tnf%C3%AE-production-by-human-monocytes-in-an-in-vitro-model-of-anti-hla-antibody-induced-antibody-dependent-cellular-cytotoxicity
#15
Bong-Ha Shin, Shili Ge, James Mirocha, Stanley C Jordan, Mieko Toyoda
BACKGROUND: We previously demonstrated that natural killer (NK) cells activated via FcγRIIIa (CD16) interactions with anti-HLA antibodies binding to peripheral blood mononuclear cells (PBMCs) in the in vitro antibody-dependent cellular cytotoxicity (ADCC) assay produced IFNγ. Here we investigate if other CD16 bearing cells are responsive to alloantigen via alloantibody in the in vitro ADCC and if the ADCC-induced cytokine reactions and cytotoxicity can be modified by the anti-interleukin 6 receptor (IL-6R) monoclonal antibody, Tocilizumab (TCZ)...
March 2017: Transplantation Direct
https://www.readbyqxmd.com/read/28356746/an-estimate-of-the-cost-of-administering-intravenous-biological-agents-in-spanish-day-hospitals
#16
Joan Miquel Nolla, Esperanza Martín, Pilar Llamas, Javier Manero, Arturo Rodríguez de la Serna, Manuel Francisco Fernández-Miera, Mercedes Rodríguez, José Manuel López, Alexandra Ivanova, Belén Aragón
OBJECTIVE: To estimate the unit costs of administering intravenous (IV) biological agents in day hospitals (DHs) in the Spanish National Health System. PATIENTS AND METHODS: Data were obtained from 188 patients with rheumatoid arthritis, collected from nine DHs, receiving one of the following IV therapies: infliximab (n=48), rituximab (n=38), abatacept (n=41), or tocilizumab (n=61). The fieldwork was carried out between March 2013 and March 2014. The following three groups of costs were considered: 1) structural costs, 2) material costs, and 3) staff costs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28353560/a-life-threatening-case-of-tafro-syndrome-with-dramatic-response-to-tocilizumab-rituximab-and-pulse-steroids-the-first-case-report-in-latin-america
#17
Fabio Freire José, Lucila Nassif Kerbauy, Guilherme Fleury Perini, Danielle Isadora Blumenschein, Denise da Cunha Pasqualin, Denise Maria Avancini Costa Malheiros, Guilherme de Carvalho Campos Neto, Fabio Pires de Souza Santos, Ronaldo Piovesan, Nelson Hamerschlak
RATIONALE: This is the report of the first case of TAFRO syndrome (Thrombocytopenia, Anasarca, myelofibrosis, Renal dysfunction, Organomegaly) in Latin America. PATIENT CONCERNS: The patient was a 61-year-old white woman of Ashkenazi Jewish descent, who presented with a history of 8 days of nausea, vomiting, and fever; severe pitting edema in both legs, ascites, splenomegaly, and palpable axillary lymph nodes. DIAGNOSES: Abdominal computed tomography (CT) showed bilateral pleural effusion and retroperitoneal lymph node enlargement...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28349061/physicochemical-and-biological-characterization-of-the-proposed-biosimilar-tocilizumab
#18
Shiwei Miao, Li Fan, Liang Zhao, Ding Ding, Xiaohui Liu, Haibin Wang, Wen-Song Tan
HS628 has been developed as a proposed biosimilar product of originator tocilizumab (Actemra®). An extensive physicochemical and biological characterization was conducted to assess similarity between HS628 and originator tocilizumab. The amino acid sequence was shown to be identical between HS628 and originator tocilizumab. The higher order structure was found to be indistinguishable from originator tocilizumab. Concerning purity and heterogeneity, HS628 was demonstrated to have similar posttranslational modifications, charge heterogeneity, size heterogeneity, and glycosylation to originator tocilizumab...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28342234/critical-contribution-of-the-interleukin-6-signal-transducer-and-activator-of-transcription-3-axis-to-vasculopathy-associated-with-systemic-sclerosis
#19
Takashi Taniguchi, Yoshihide Asano, Takemichi Fukasawa, Ayumi Yoshizaki, Shinichi Sato
Reflecting the critical role of interleukin (IL)-6 in systemic sclerosis (SSc), tocilizumab, an anti-IL-6 receptor antibody, is currently under a global phase III trial against skin sclerosis of this disease. We here demonstrate that the IL-6/signal transducer and activator of transcription 3 axis is broadly activated in various cell types in the lesional skin of SSc patients irrespective of disease subtypes, especially in endothelial cells. Importantly, 12 monthly infusions of tocilizumab improved nailfold capillary changes as well as skin sclerosis in a patient with diffuse cutaneous SSc...
March 24, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28337062/successful-treatment-of-beh%C3%A3-et-s-uveitis-with-tocilizumab
#20
F Alokaily, A Al Saati, A Jawad
A 33-year-old man with history of lymphoma was misdiagnosed as multiple sclerosis (MS) 18 months previously, developed intermediate uveitis, unresponsive to interferon, and corticosteroids. A diagnosis of Behçet's disease (BD) was made on the basis of recurrent orogenital ulceration, erythema nodosum, and a positive pathergy test. The patient was started on Tocilizumab and experienced an improvement in visual acuity and intraocular inflammation over the following 2 weeks. In patients with BD-related uveitis, Tocilizumab can be an effective alternative to anti-tumor necrosis factor alpha medications...
January 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
keyword
keyword
5841
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"